|
GE Healthcare Launches Sterile Genderless Connector for Disposable Biopharmaceutical Production
Philadelphia, PA (March 23, 2008) -- GE Healthcare, a unit of General Electric (NYSE: GE), launched of a range of sterile genderless connectors as part of its ReadyToProcess™ portfolio of ready-to-use bioprocessing systems. GE Healthcare has acquired exclusive rights to the Disposable Aseptic Connector (DAC) developed by BioQuate Inc, and is now a key component in GE Healthcare's fully disposable technology offering.
The DAC launch furthers GE Healthcare's commitment to increasing efficiency and decreasing time-to-market for customers by eliminating cleaning and validation steps through use of its ready-to-use and single use disposable technologies in biomanufacturing. The genderless DAC reduces complexity for customers by reducing parts inventory and requires no unique operator skills, power, calibration, or servicing.
The licensing deal includes further agreements with Pall Corporation, settling Pall Corporation's patent infringement lawsuit with BioQuate Inc. GE Healthcare and Pall have entered into mutual patent licensing agreements that will enable both companies to further develop their respective disposable connective technologies.
"These agreements build on our acquisition of Wave Biotech and our launch of the ReadyToProcess portfolio. With our ready-to-use offering, we're committing to saving customers' time, operating expenses and increasing speed, flexibility and capacity of production," said Nigel Darby, Chief Technology Officer, Life Sciences, GE Healthcare.
"I am very pleased to join forces with GE Healthcare to bring genderless, disposable aseptic connectors to the market. GE Healthcare has a significant history in the market and will provide a vehicle to bring our DAC connection technology to a broad range of applications as well as providing a worldwide channel to the biotech market," said Ted Johnson, CEO BioQuate.
GE Healthcare's new ReadyToProcess portfolio is designed to meet the biopharmaceutical industry's need for increased speed, simplicity and safety for all areas of bioprocessing, from cell culture and fermentation to final purification. As part of GE Healthcare's strategic development of disposable and ready-to-use biopharmaceutical processing technologies, the products available today in the ReadyToProcess portfolio include single-use WAVE TM technologies and a set of newly-developed, ready-to-use filtration and chromatography tools.
ReadyToProcess technologies allow considerable advantages over conventional methods used in bioprocessing, including: higher project throughput and shorter time-to-market due to the elimination of cleaning and cleaning validation steps, elimination of cross contamination problems and reduced training and certification of employees due to the convenience of a ready-to-use format.
About BioQuate
BioQuate is a privately held Florida corporation that provides today's biopharm industry with patented, innovative disposable devices that improve fluid throughput and maintain sterile system integrity. The core competency of BioQuate is in developing genderless connection platforms to meet specific needs within the industry.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.
GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. www.gehealthcare.com, GE Press Release
BioQuate Asserts No Infringement of Pall Patent
Clearwater, FL (April 24, 2007) -- After careful review of the Pall Lawsuit Complaint, BioQuate asserts that the BioQuate Disposable Aseptic Connector (DAC) does not infringe the referenced Pall patent; in addition, it is the company position that the Pall Patent is invalid for a variety of reasons; as a result, BioQuate intends to vigorously defend their position and is confident they will prevail in a court of law.
BioQuate is a privately held Florida corporation that provides today's biotech industry with patented, innovative disposable devices that improve media throughput and maintain sterile system integrity. The BioQuate Disposable Aseptic Connector (DAC) is a genderless connection system based on ISO standards; the connectors are available in various hose barb sizes up to 3/4", as well as, a DAC / sanitary coupling combination.
BioQuate Responds to Pall Infringement Suit
Clearwater,
FL (March 21, 2007) -- BioQuate, Incorporated
of Clearwater, Florida received a complaint from Pall Corporation
alleging that the BioQuate Disposable Aseptic Connector infringes
a Pall patent. BioQuate has strong defenses to the suit
and is confident that it will prevail against Pall Corporation.
BioQuate is a privately held Florida corporation that provides
today's biotech industry with innovative disposable devices that
improve liquid media throughput and maintain sterile system integrity. In
all situations, BioQuate remains focused on the technical needs
of its customers.
|
